Healthcare
Wednesday, January 4, 2017
BRIEF-Evoke Phase 3 diabetic gastroparesis trial did not meet primary endpoint
* Evoke provides additional data demonstrating statistically
significant benefit for Gimoti in moderate to severe patients in
phase 3 diabetic gastroparesis trial
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment